No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
003020 Hefei Lifeon Pharmaceutical
- 17.82
- -0.30-1.66%
Market Closed Jan 7 15:00 CST
3.41BMarket Cap19.58P/E (TTM)
18.10High17.53Low13.19KlotVolume18.10Open18.12Pre Close23.41MTurnover0.96%Turnover Ratio15.06P/E (Static)191.57MShares22.0652wk High1.97P/B2.46BFloat Cap13.3252wk Low19.93Limit Up138.04MShs Float36.80Historical High16.31Limit Down3.15%Amplitude12.36Historical Low0.42Dividend TTM17.75Avg Price7.33KlotAsk2.34%Div YieldTTM100Lot Size5.67KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Hefei Lifeon Pharmaceutical: The listing application for the Active Pharmaceutical Ingredient Relugolix has been accepted.
Express News | Hefei Lifeon Pharmaceutical: Received the acceptance notice for the listing application of Active Pharmaceutical Ingredient Ritalin.
Hefei Lifeon Pharmaceutical (003020.SZ): The application for the listing of the Active Pharmaceutical Ingredient Ceftazidime has been approved.
Gelonghui reported on December 20 that Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, Hefei Lifeon Pharmaceutical Co., Ltd. received the approval notification for the listing application of the chemical raw material of Gatifloxacin issued by the National Medical Products Administration. Gatifloxacin is a cyclopropyl fluoroquinolone drug, a fourth-generation broad-spectrum antibacterial agent developed by the Japan-based Kyowa Kirin Co., Ltd., primarily used to treat various infectious diseases caused by sensitive pathogens.
Express News | Today, five A-shares registered for equity, with lb group co., ltd., ju one technology, and china citic bank corporation offering the largest dividends.
Hefei Lifeon Pharmaceutical (003020.SZ) plans to permanently supplement working capital using the surplus raised funds.
On December 9, 2023, Hefei Lifeon Pharmaceutical (003020.SZ) announced that the fifth board of directors held its seventeenth meeting and the fifth supervisory board held its fifteenth meeting on December 9, 2024, which reviewed and approved the proposal on the permanent use of surplus raised funds to supplement working capital. It agreed to permanently supplement working capital with surplus raised funds after the completion of the fundraising investment projects for the company's daily production and operation. This proposal needs to be submitted to the company's shareholders' meeting for approval. Given that the company's fundraising investment projects have reached the planned usable status, and the payment cycle for the performance bond and final payment for the fundraising investment projects is long, in order to provide.
Hefei Lifeon Pharmaceutical (003020.SZ) 2024 mid-term profit distribution plan: proposes to distribute 2 yuan for every 10 shares.
On December 9, Gelonghui reported that hefei lifeon pharmaceutical (003020.SZ) announced the proposed profit distribution plan for the first half of 2024 as follows: The profit distribution will be based on the total share capital as of the date of the rights distribution. The company plans to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders. Based on this preliminary calculation, the total cash dividend proposed to be distributed is 38,252,100 yuan (tax included).